Fundamental Analysis of SIGILON THERAPEUTICS INC(NASDAQ:SGTX) stock

Fundamental Rating

Taking everything into account, SGTX scores 1 out of 10 in our fundamental rating. SGTX was compared to 587 industry peers in the Biotechnology industry. SGTX may be in some trouble as it scores bad on both profitability and health. SGTX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SGTX has reported negative net income.

In the past year SGTX has reported a negative cash flow from operations.

SGTX had negative earnings in each of the past 5 years.

SGTX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The profitability ratios for SGTX are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SGTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

SGTX has more shares outstanding than it did 1 year ago.

Compared to 1 year ago, SGTX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -4.91, we must say that SGTX is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -4.91, SGTX is not doing good in the industry: 68.20% of the companies in the same industry are doing better.

SGTX has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.

SGTX has a Debt to Equity ratio of 0.31. This is in the lower half of the industry: SGTX underperforms 73.64% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.31
Debt/FCF	N/A
Altman-Z	-4.91

ROIC/WACCN/A

WACC9.94%

2.3 Liquidity

SGTX has a Current Ratio of 2.23. This indicates that SGTX is financially healthy and has no problem in meeting its short term obligations.

SGTX's Current ratio of 2.23 is on the low side compared to the rest of the industry. SGTX is outperformed by 80.27% of its industry peers.

A Quick Ratio of 2.23 indicates that SGTX has no problem at all paying its short term obligations.

SGTX's Quick ratio of 2.23 is on the low side compared to the rest of the industry. SGTX is outperformed by 78.57% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.23
Quick Ratio	2.23

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SGTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -327.88%.

SGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 49.27%.

The Revenue has been decreasing by -2.95% on average over the past years.

EPS 1Y (TTM)-327.88%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-595.35%

Revenue 1Y (TTM)49.27%

Revenue growth 3Y-2.95%

Revenue growth 5YN/A

Revenue growth Q2Q53.49%

3.2 Future

The Earnings Per Share is expected to grow by 13.31% on average over the next years. This is quite good.

SGTX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.28% yearly.

EPS Next Y-34.47%

EPS Next 2Y-35.84%

EPS Next 3Y-16.93%

EPS Next 5Y13.31%

Revenue Next Year19.62%

Revenue Next 2Y10.18%

Revenue Next 3Y6.68%

Revenue Next 5Y-0.28%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGTX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as SGTX's earnings are expected to decrease with -16.93% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-35.84%

EPS Next 3Y-16.93%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SGTX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SIGILON THERAPEUTICS INC

NASDAQ:SGTX (8/10/2023, 7:02:09 PM)

After market: 23 +0.53 (+2.36%)

22.47

-0.59 (-2.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap56.50M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.19

Health

		Industry Rank	Sector Rank
Debt/Equity	0.31
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.23
Quick Ratio	2.23
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-327.88%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-34.47%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)49.27%

Revenue growth 3Y-2.95%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

SIGILON THERAPEUTICS INC (SGTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens